Are randomized trials obsolete or more important than ever in the genomic era?

Genome Medicine

Volumn 5, Issue 4, 2013, Pages

  Ioannidis, John P A ^a,b   Khoury, Muin J ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYTOCHROME P450 2C19; DASATINIB; HLA B ANTIGEN; MARAVIROC; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; FOLLOW UP; GENETIC ASSOCIATION; GENOMICS; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE;

EID: 84875946700     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm436     Document Type: Article

References (10)

1. Antman E, Weiss S, Loscalzo J. Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med 2012, 4:367-383.
2. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008, 14:5984-5993.
3. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Per Med 2011, 8:161-173.
4. Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies/
5. Table of Pharmacogenomic Biomarkers in Drug Labels. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
6. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A for PREDICT-1 Study Team HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579. Benbow A for PREDICT-1 Study Team.
7. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
8. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science 2011, 334:1230-1232.
9. Ioannidis JP. Mega-trials for blockbusters. JAMA 2013, 309:239-240.
10. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008, 82:593-599.